INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57401, 0, 'Insulin human', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57402, 0, 'Insulin human (isophane)', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57403, 0, 'Insulin human (isophane)', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57404, 0, 'Insulin human (isophane)', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57405, 20060, 'Interferon alfa-2a, Recombinant', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57406, 20061, 'Interferon alfa-2a, Recombinant', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57407, 20883, 'Interferon alfa-2a, Recombinant', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57408, 20884, 'Interferon alfa-2a, Recombinant', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57409, 25815, 'Interferon alfa-2a, Recombinant', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57410, 25816, 'Interferon alfa-2a, Recombinant', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57411, 26243, 'Interferon alfa-2a, Recombinant', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57412, 20060, 'Interferon alfa-2a, Recombinant', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57413, 20061, 'Interferon alfa-2a, Recombinant', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57414, 20883, 'Interferon alfa-2a, Recombinant', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57415, 20884, 'Interferon alfa-2a, Recombinant', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57416, 25815, 'Interferon alfa-2a, Recombinant', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57417, 25816, 'Interferon alfa-2a, Recombinant', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57418, 26243, 'Interferon alfa-2a, Recombinant', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57419, 20060, 'Interferon alfa-2a, Recombinant', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57420, 20061, 'Interferon alfa-2a, Recombinant', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57421, 20883, 'Interferon alfa-2a, Recombinant', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57422, 20884, 'Interferon alfa-2a, Recombinant', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57423, 25815, 'Interferon alfa-2a, Recombinant', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57424, 25816, 'Interferon alfa-2a, Recombinant', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57425, 26243, 'Interferon alfa-2a, Recombinant', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57426, 20060, 'Interferon alfa-2a, Recombinant', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57427, 20061, 'Interferon alfa-2a, Recombinant', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57428, 20883, 'Interferon alfa-2a, Recombinant', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57429, 20884, 'Interferon alfa-2a, Recombinant', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57430, 25815, 'Interferon alfa-2a, Recombinant', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57431, 25816, 'Interferon alfa-2a, Recombinant', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57432, 26243, 'Interferon alfa-2a, Recombinant', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57433, 20060, 'Interferon alfa-2a, Recombinant', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57434, 20061, 'Interferon alfa-2a, Recombinant', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57435, 20883, 'Interferon alfa-2a, Recombinant', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57436, 20884, 'Interferon alfa-2a, Recombinant', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57437, 25815, 'Interferon alfa-2a, Recombinant', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57438, 25816, 'Interferon alfa-2a, Recombinant', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57439, 26243, 'Interferon alfa-2a, Recombinant', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57440, 20060, 'Interferon alfa-2a, Recombinant', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57441, 20061, 'Interferon alfa-2a, Recombinant', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57442, 20883, 'Interferon alfa-2a, Recombinant', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57443, 20884, 'Interferon alfa-2a, Recombinant', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57444, 25815, 'Interferon alfa-2a, Recombinant', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57445, 25816, 'Interferon alfa-2a, Recombinant', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57446, 26243, 'Interferon alfa-2a, Recombinant', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57447, 20060, 'Interferon alfa-2a, Recombinant', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57448, 20061, 'Interferon alfa-2a, Recombinant', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57449, 20883, 'Interferon alfa-2a, Recombinant', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57450, 20884, 'Interferon alfa-2a, Recombinant', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57451, 25815, 'Interferon alfa-2a, Recombinant', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57452, 25816, 'Interferon alfa-2a, Recombinant', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57453, 26243, 'Interferon alfa-2a, Recombinant', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57454, 20060, 'Interferon alfa-2a, Recombinant', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57455, 20061, 'Interferon alfa-2a, Recombinant', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57456, 20883, 'Interferon alfa-2a, Recombinant', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57457, 20884, 'Interferon alfa-2a, Recombinant', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57458, 25815, 'Interferon alfa-2a, Recombinant', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57459, 25816, 'Interferon alfa-2a, Recombinant', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57460, 26243, 'Interferon alfa-2a, Recombinant', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57461, 20060, 'Interferon alfa-2a, Recombinant', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57462, 20061, 'Interferon alfa-2a, Recombinant', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57463, 20883, 'Interferon alfa-2a, Recombinant', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57464, 20884, 'Interferon alfa-2a, Recombinant', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57465, 25815, 'Interferon alfa-2a, Recombinant', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57466, 25816, 'Interferon alfa-2a, Recombinant', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57467, 26243, 'Interferon alfa-2a, Recombinant', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57468, 20060, 'Interferon alfa-2a, Recombinant', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57469, 20061, 'Interferon alfa-2a, Recombinant', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57470, 20883, 'Interferon alfa-2a, Recombinant', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57471, 20884, 'Interferon alfa-2a, Recombinant', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57472, 25815, 'Interferon alfa-2a, Recombinant', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57473, 25816, 'Interferon alfa-2a, Recombinant', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57474, 26243, 'Interferon alfa-2a, Recombinant', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57475, 0, 'Insulin human (zinc)', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57476, 0, 'Insulin human (zinc)', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57477, 0, 'Insulin human (zinc)', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57478, 4034, 'Interferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57479, 18116, 'Interferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57480, 18117, 'Interferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57481, 20910, 'Interferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57482, 20911, 'Interferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57483, 4034, 'Interferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57484, 18116, 'Interferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57485, 18117, 'Interferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57486, 20910, 'Interferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57487, 20911, 'Interferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57488, 4034, 'Interferon alfa-2b', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57489, 18116, 'Interferon alfa-2b', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57490, 18117, 'Interferon alfa-2b', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57491, 20910, 'Interferon alfa-2b', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57492, 20911, 'Interferon alfa-2b', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57493, 4034, 'Interferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57494, 18116, 'Interferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57495, 18117, 'Interferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57496, 20910, 'Interferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57497, 20911, 'Interferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57498, 4034, 'Interferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57499, 18116, 'Interferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (57500, 18117, 'Interferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '', 'DDInter', 0);
